pembrolizumab
merck
['pembro', 'hodgkin', 'lymsm', 'cml']
#17icml hodgkin session: presents phase 2 trial of frontline pembro monotherapy
- 25 pts (median age 77, basically all advanced-stage)
- orr 72% (cr 32%)
- 2-yr os 83%
- 52% grade 3+ aes (!!!), no treatment-related deaths
definite activity, but quite toxic #lymsm 
Lymphoma doc & patient-reported outcomes researcher in #lymsm and #mmsm @CUHematology. Founder of https://t.co/kN6qeGFEox, @inTrainingDoc & @inHouseMag. 🏳️‍🌈